Edwards Lifesciences
About: Spun off from Baxter International in 2000, Edwards Lifesciences designs, manufactures, and markets a range of medical devices and equipment for advanced stages of structural heart disease. It has established itself as a leader across key products, including surgical tissue heart valves, transcatheter valve technologies, surgical clips, and catheters. The firm derives about 55% of its total sales from outside the US.
Employees: 19,800
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
147% more call options, than puts
Call options by funds: $733M | Put options by funds: $296M
4.22% less ownership
Funds ownership: 82.76% [Q2] → 78.53% (-4.22%) [Q3]
10% less funds holding
Funds holding: 1,275 [Q2] → 1,150 (-125) [Q3]
27% less repeat investments, than reductions
Existing positions increased: 352 | Existing positions reduced: 483
32% less capital invested
Capital invested by funds: $46B [Q2] → $31.3B (-$14.8B) [Q3]
47% less first-time investments, than exits
New positions opened: 139 | Existing positions closed: 264
57% less funds holding in top 10
Funds holding in top 10: 14 [Q2] → 6 (-8) [Q3]
Research analyst outlook
16 Wall Street Analysts provided 1 year price targets over the past 3 months
16 analyst ratings
Canaccord Genuity William Plovanic 67% 1-year accuracy 26 / 39 met price target | 7%downside $63 | Hold Maintained | 25 Oct 2024 |
JP Morgan Robbie Marcus 63% 1-year accuracy 12 / 19 met price target | 15%upside $78 | Neutral Maintained | 25 Oct 2024 |
Piper Sandler Adam Maeder 63% 1-year accuracy 10 / 16 met price target | 3%upside $70 | Neutral Maintained | 25 Oct 2024 |
Truist Securities Richard Newitter 66% 1-year accuracy 31 / 47 met price target | 3%upside $70 | Hold Maintained | 25 Oct 2024 |
Baird David Rescott 81% 1-year accuracy 13 / 16 met price target | 0%upside $68 | Neutral Maintained | 25 Oct 2024 |
Financial journalist opinion
Based on 387 articles about EW published over the past 30 days
